Azure Yarbrough

Ms. Azure Yarbrough


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
APAmy L. Patton
Amy L. Patton
KSKathryn A. Seely
Kathryn A. Seely
AYAzure Yarbrough
Azure Yarbrough
WFWilliam Fantegrossi
William Fantegrossi
LJLaura P. James
Laura P. James
ARAnna Radominska-Pandya
Anna Radominska-Pandya

12 May 2016 in Journal of Biosciences
Verified
Journal Article
Closed access
PDF file
KMKatherine Maringer
Katherine Maringer
AYAzure Yarbrough
Azure Yarbrough
SSSunder Sims-Lucas
Sunder Sims-Lucas
ESEntsar Saheb
Entsar Saheb
SJSanaa Jawed
Sanaa Jawed
JBJohn Bush
John Bush

26 September 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RHRachel D. Hutchison
Rachel D. Hutchison
BFBenjamin M. Ford
Benjamin M. Ford
LFLirit N. Franks
Lirit N. Franks
CWCatheryn D. Wilson
Catheryn D. Wilson
AYAzure Yarbrough
Azure Yarbrough
PPPaul L. Prather
Paul L. Prather
Recreational use of marijuana is associated with few adverse effects, but abuse of synthetic cannabinoids (SCBs) can result in anxiety, psychosis, chest pain, seizures and death. To potentially explain higher toxicity associated with SCB use, we hypothesized that AB-PINACA, a common second generation SCB, exhibits atypical pharmacodynamic properties at CB1 cannabinoid receptors (CB1Rs) and/or a distinct metabolic profile when compared to Δ9-tetrahydrocannabinol (Δ9-THC), the principal psychoactive cannabinoid present in marijuana. Liquid chromatography tandem mass spectrometry (LC/MS) identified AB-PINACA and monohydroxy metabolite(s) as primary phase I metabolites (4OH-AB-PINACA and/or 5OH-AB-PINACA) in human urine and serum obtained from forensic samples. In vitro experiments demonstrated that when compared to Δ9-THC, AB-PINACA exhibits similar affinity for CB1Rs, but greater efficacy for G-protein activation and higher potency for adenylyl cyclase inhibition. Chronic treatment with AB-PINACA also results in greater desensitization of CB1Rs (e.g., tolerance) than Δ9-THC. Importantly, monohydroxy metabolites of AB-PINACA retain affinity and full agonist activity at CB1Rs. Incubation of 4OH-AB-PINACA and 5OH-AB-PINACA with human liver microsomes (HLMs) results in limited glucuronide formation when compared to that of JWH-018-M2, a major monohydroxylated metabolite of the first generation SCB JWH-018. Finally, AB-PINACA and 4OH-AB-PINACA are active in vivo, producing CB1R-mediated hypothermia in mice. Taken collectively, the atypical pharmacodynamic properties of AB-PINACA at CB1Rs relative to Δ9-THC (e.g., higher potency/efficacy and greater production of desensitization), coupled with an unusual metabolic profile (e.g., production of metabolically stable active phase I metabolites) may contribute to the pronounced adverse effects observed with abuse of this SCB compared to marijuana.

13 May 2020 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
APAnna Pinson
Anna Pinson
AYAzure Yarbrough
Azure Yarbrough
JBJohn M. Bush
John M. Bush
CCChristian V. Cabanlong
Christian V. Cabanlong
ASAmal M. Shoeib
Amal M. Shoeib
ARAnna Radominska-Pandya
Anna Radominska-Pandya

31 January 2020 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
SJSabrina Jones
Sabrina Jones
AYAzure Yarbrough
Azure Yarbrough
WFWilliam E. Fantegrossi
William E. Fantegrossi
PPPaul L. Prather
Paul L. Prather
JBJohn M. Bush
John M. Bush
RFRyoichi Fujiwara
Ryoichi Fujiwara
Synthetic cannabinoids (SCBs), designer drugs marketed as legal alternatives to marijuana, act as ligands to cannabinoid receptors; however, they have increased binding affinity and potency, resulting in toxicity symptoms such as cardiovascular incidents, seizures, and potentially death. N‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1H‐indole‐3‐carboxamide (STS‐135) is a third generation SCB. When incubated with hepatocytes, it undergoes oxidation, hydrolysis, and glucuronidation, resulting in 29 metabolites, with monohydroxy STS‐135 (M25) and dihydroxy STS‐135 (M21) being the predominant metabolites. The enzymes responsible for this oxidative metabolism were unknown. Thus, the aim of this study was to identify the cytochrome P450 (P450s or CYPs) enzymes involved in the oxidative metabolism of STS‐135. In this study, STS‐135 was incubated with liver, intestinal, and brain microsomes and recombinant P450s to determine the enzymes involved in its metabolism. Metabolite quantification was carried out using ultra‐performance liquid chromatography. STS‐135 was extensively metabolized in HLMs and HIMs. Screening assays indicated CYP3A4 and CYP3A5 could be responsible for STS‐135’s oxidation. Through incubations with genotyped HLMs, CYP3A4 was identified as the primary oxidative enzyme. Interestingly, CYP2J2, a P450 isoform expressed in cardiovascular tissues, showed high activity towards the formation of M25 with a Km value of 11.4 μmol/L. Thus, it was concluded that STS‐135 was primarily metabolized by CYP3A4 but may have extrahepatic metabolic pathways as well. Upon exposure to STS‐135, individuals with low CYP3A4 activity could retain elevated blood concentration, resulting in toxicity. Additionally, CYP2J2 may aid in protecting against STS‐135‐induced cardiovascular toxicity.

20 April 2018 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
QAQudes Al-Anbaky
Qudes Al-Anbaky
ZAZeiyad Al-Karakooly
Zeiyad Al-Karakooly
RCRichard Connor
Richard Connor
LWLisa Williams
Lisa Williams
AYAzure Yarbrough
Azure Yarbrough
Nawab AliNawab Ali
Nawab Ali